Plus Therapeutics Inc Forecast, price target & analysts
Plus Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Plus Therapeutics Inc Classifications & Recommendation:
Plus Therapeutics Inc Price Target
| Target Price | $3.06 |
| Price | $0.48 |
| Potential |
540.44%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Plus Therapeutics Inc 2026 .
The average Plus Therapeutics Inc target price is $3.06.
This is
540.44%
register free of charge
$21.53
4,405.02%
register free of charge
$3.03
534.16%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Plus Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Plus Therapeutics Inc stock has an average upside potential 2026 of
540.44%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 5.82 | 6.00 |
| 18.53% | 3.02% | |
| EBITDA Margin | -240.03% | -204.14% |
| 7.13% | 14.95% | |
| Net Margin | -223.02% | -1,029.73% |
| 17.79% | 361.71% |
5 Analysts have issued a sales forecast Plus Therapeutics Inc 2025 . The average Plus Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Plus Therapeutics Inc EBITDA forecast 2025. The average Plus Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Plus Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Plus Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.95 | -0.67 |
| 54.01% | 65.64% | |
| P/E | negative | |
| EV/Sales | 6.99 |
5 Analysts have issued a Plus Therapeutics Inc forecast for earnings per share. The average Plus Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Plus Therapeutics Inc...
Current Plus Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Aug 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jun 25 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Jun 05 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | May 05 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Sep 03 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Aug 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 27 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jun 25 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Jun 05 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
May 05 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 21 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
